Amyris Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Dive Deeper Into the Growth Paths Behind the Analysis
This Amyris Balanced Scorecard Analysis gives you a structured view of the company's financial, customer, internal process, and learning and growth priorities. The page already shows a real preview of the actual report content, so you can review the format before buying. Purchase the full version to access the complete ready-to-use analysis.
Benefits
Optimized Fermentation Yields
Optimized fermentation yields let Amyris tie internal process metrics to unit economics, but no 2025 fiscal figures were publicly reported after its 2023 bankruptcy and delisting. In its last public reports, the company tracked grams-per-liter to push at least 5 key molecules toward lower cost per batch. That data loop helped turn yeast-strain lab gains into factory runs with fewer failed batches and tighter margins.
B2B Partnership Velocity
B2B partnership velocity tracks how fast Amyris can move from strain design to commercial royalty checks. That matters because shorter cycles can bring in up-front fees sooner and protect cash, especially when a pipeline has more than 10 active ingredient collaborations. It is a clean way to judge whether partner deals are turning science into near-term revenue.
Precision Resource Allocation
Precision resource allocation pushes Amyris to fund bio-foundry capacity, not speculative R&D, so capital goes to products that can actually scale. In 2023, Amyris reported $314.6 million in revenue and still entered Chapter 11, showing how fast weak project selection can destroy cash. Tracking Green Premium cuts on 4 core products helps stop losses on molecules that cannot beat petroleum-based rivals.
That focus is the only way the plan can support a positive EBITDA path by 2027.
Strategic IP Asset Tracking
Under Learning and Growth, strategic IP asset tracking measures how Amyris acquires and defends synthetic biology patents, which matters because the company filed Chapter 11 in 2023 and the value of its know-how depends on legal protection. A 15% annual rise in proprietary fermentation pathways can widen the moat around high-margin formulas and slow commoditization. It also ties talent output to future balance sheet strength by turning R&D skill into defendable assets.
Decarbonization Value Quantifying
A decarbonization scorecard lets Amyris measure the carbon offset delivered to its 3 largest industrial clients, turning sustainability claims into audit-ready data. That matters because cosmetics buyers are under pressure to cut Scope 3 emissions, and auditable impact proof can support stickier contracts and higher pricing for 100% plant-derived squalane and hemisqualane. In the global chemical supply chain, ESG reporting becomes a sales tool, not just a compliance task.
Why tighter cash use and faster monetization matter after Amyris' Chapter 11
Benefits center on tighter cash use, faster partner monetization, and clearer ESG proof. Amyris last reported 2023 revenue of $314.6 million, then filed Chapter 11 and delisted, so no 2025 fiscal figures were public. That makes scorecard use even more about conversion speed, margin control, and audit-ready carbon data.
| Metric | Latest public | Signal |
|---|---|---|
| Revenue | $314.6M, 2023 | Scale |
| Status | Chapter 11, 2023 | Liquidity risk |
| 2025 fiscal data | Not public | Limits disclosure |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Biological Variable Sensitivity
Biological variable sensitivity makes Amyris's scorecard hard to standardize, because yeast fermentation can swing 5% to 10% in metabolic behavior even when operators do the same thing. That means a red KPI can reflect biological drift, not weak management, so the Balanced Scorecard may misread control gaps. In a process this noisy, even small batch shifts can blur cost, yield, and cycle-time targets.
Data Integration Latency
Amyris's scorecard can lag by about 90 days because lab results move daily, but U.S. quarterly reporting only updates every 3 months. That delay can matter when cash is tight; Amyris filed Chapter 11 on August 9, 2023, with liabilities in the $1 billion to $10 billion range. So 2026 decision-makers may see a clean scorecard only after the best capital-allocation window has closed.
Short-Term Profit Pressure
Heavy focus on Financial KPIs can push Amyris engineers to squeeze more out of current strains instead of funding longer 12-month research bets. That is risky for a company that filed Chapter 11 in 2023 after years of cash burn and debt pressure, because lenders often demand faster payback, not slower science. The trade-off can delay the next high-value molecule and weaken long-term pipeline strength.
Complex Intangible Valuation
Complex intangible valuation is a weak spot in Amyris Balanced Scorecard Analysis. Pricing a library of millions of yeast strain variants is still subjective, so the Learning and Growth score can look stronger than the real cash return from the platform. That matters because Amyris showed how weak conversion can hurt hard: despite heavy R&D, it later failed to turn that science into durable sales or profits.
Foundry Over-Optimization Risks
Efficiency-heavy scorecards can push Amyris to run about 95% of bio-foundry capacity on low-margin work, crowding out test runs for new strains and process tweaks. That matters because Amyris already filed Chapter 11 in 2023, showing how little cushion can turn a planning win into a cash trap. Without slack, the team loses speed to pivot toward high-demand pharma ingredients when a public health shock hits. It is a throughput gain, but a resilience loss.
Amyris Scorecard Missed the Cash Squeeze
Amyris's scorecard is weak on control and timing: fermentation noise can distort KPIs, and quarterly reporting can miss fast cash shifts. In Chapter 11 on August 9, 2023, Amyris listed liabilities of $1 billion to $10 billion, so 2025-style scorecard updates could still arrive too late to fix capital strain.
| Risk | Data point |
|---|---|
| Biology noise | 5% to 10% |
| Cash shock | Chapter 11, Aug. 9, 2023 |
| Liabilities | $1B to $10B |
| 2025 FY filing | Not disclosed |
What You See Is What You Get
Amyris Reference Sources
This is the actual Amyris Balanced Scorecard analysis document you'll receive upon purchase-no samples, no placeholders, just the full report. The preview below is taken directly from the same file you'll download after checkout. Buy now to unlock the complete, detailed version in full.
Frequently Asked Questions
Amyris utilizes the framework to align biological strain performance with market-readiness timelines for its yeast-based products. By tracking metrics like a 15% reduction in strain-engineering cycles, management ensures that scientific breakthroughs translate into scalable commercial products. This prevents R&D teams from focusing on scientifically interesting but commercially unviable paths, maintaining a portfolio that supports 12 or more active, revenue-generating ingredient molecules.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.